Endocrine Abstracts

Background: Resistin was originally proposed in animal models as a link between obesity and insulin resistance, but later studies in humans have shown a divergent role. Yet, resistin seems to be involved in the development of atherosclerosis in humans by promoting the formation of foam cells; further, its expression is induced by oxidized low-density lipoproteins (LDL) in human macrophages.Methods: We assessed the relationships between resistin and marke...

Background: There is evidence that rosiglitazone may increase cardiovascular risk and, on this basis, this agent has been recently advised for treatment of type-2 diabetes. Yet, its effects on fasting and postprandial atherogenic dyslipidemia are still not fully elucidated.Methods: In an open-label study rosiglitazone (4 mg/day for 12 weeks) was added on top of a maximum of two oral antidiabetic drugs to 18 patients with adequately controlled type-2 diab...